New Migraine Study Findings Reported from University of Verona (Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients).
In: Pain & Central Nervous System Week, 2024-03-15, S. 710-710
serialPeriodical
Zugriff:
A recent study conducted at the University of Verona in Italy examined the use of anti-CGRP monoclonal antibodies (mAbs) for migraine prophylaxis. The study analyzed data from 209 patients who were prescribed subcutaneous injections of fremanezumab, galcanezumab, or erenumab between 2019 and 2022. The results showed that erenumab and galcanezumab were effective in reducing migraine symptoms, while fremanezumab did not achieve statistical significance, likely due to the small sample size. Adverse events were reported by 17.5% of patients, with only 2.4% discontinuing treatment due to side effects. The study suggests that anti-CGRP and anti-CGRP receptor mAbs are both safe and effective for migraine patients, but further research is needed to validate these findings. [Extracted from the article]
Copyright of Pain & Central Nervous System Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
New Migraine Study Findings Reported from University of Verona (Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients).
|
---|---|
Zeitschrift: | Pain & Central Nervous System Week, 2024-03-15, S. 710-710 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6394 (print) |
Schlagwort: |
|
Sonstiges: |
|